Glycotherapy: A New Paradigm in Breast Cancer Research

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Breast cancer remains a leading cause of mortality despite extensive research and resources.
• Current therapies face challenges including drug resistance, severe side effects, high costs, and limited efficacy.
• A holistic approach targeting cancer cell and microenvironment interactions is needed.

Purpose of the Study:

• To investigate the efficacy of Tunicamycin, a small molecule inhibitor of N-glycosylation, as a potential breast cancer therapeutic.
• To elucidate the mechanisms underlying Tunicamycin's anti-cancer effects.

Main Methods:

• Tunicamycin was tested for its ability to inhibit angiogenesis in vitro and in vivo.
• Its effect on breast tumor progression was evaluated in preclinical mouse models across multiple subtypes.
• Mechanistic studies explored the role of endoplasmic reticulum (ER) stress, unfolded protein response (UPR) signaling, and Wnt signaling.

Main Results:

• Tunicamycin demonstrated quantitative inhibition of angiogenesis both in vitro and in vivo.
• It significantly inhibited breast tumor progression in preclinical models of multiple subtypes with no observed toxicity.
• Mechanistic investigations revealed Tunicamycin induces apoptotic death in cancer and endothelial cells via ER stress-UPR signaling and interferes with Wnt signaling.

Conclusions:

• Tunicamycin shows significant promise as a novel glycotherapy for treating all subtypes of breast cancer.
• Its ability to inhibit angiogenesis and tumor progression with zero toxicity positions it as a potential superior alternative to current therapies.